These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22611756)

  • 1. Combined expression of p161NK4a and p27Kip1, but not p21WAF1, differentiates endocervical from endometrial adenocarcinoma.
    Abu Backer FM; Mustapha NR; Othman NH
    Anal Quant Cytol Histol; 2011 Oct; 33(5):283-8. PubMed ID: 22611756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological comparison of adenocarcinoma of cervix and endometrium using cell cycle markers: P16ink4a, P21waf1, and p27Kip1 on 132 cancers.
    Abu Backer FM; Nik Mustapha NR; Othman NH
    Infect Dis Obstet Gynecol; 2011; 2011():857851. PubMed ID: 22114462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of immunohistochemistry in differential diagnosis of endometrial carcinoma].
    Wu HW; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):784-8. PubMed ID: 23302346
    [No Abstract]   [Full Text] [Related]  

  • 4. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.
    Saad RS; Mashhour M; Noftech-Mozes S; Ismiil N; Dubé V; Ghorab Z; Faragalla H; Khalifa MA
    Int J Gynecol Pathol; 2012 Jan; 31(1):57-65. PubMed ID: 22123724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Kok LF; Wu TS; Cheng YW; Wang PH; Yue CH; Tyan YS
    Arch Gynecol Obstet; 2010 May; 281(5):845-50. PubMed ID: 19847454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mesonephric hyperplasia in uterine cervix: report of two cases].
    Zeng Y; Wu Y; Zhu X; Zhang S; Gu P; Zhu H; Qiu W; Yi X
    Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):339-40. PubMed ID: 25030871
    [No Abstract]   [Full Text] [Related]  

  • 8. P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations.
    Caponio MA; Addati T; Popescu O; Petroni S; Rubini V; Centrone M; Trojano G; Simone G
    Cancer Biomark; 2014; 14(2-3):169-75. PubMed ID: 24878818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
    Reid-Nicholson M; Iyengar P; Hummer AJ; Linkov I; Asher M; Soslow RA
    Mod Pathol; 2006 Aug; 19(8):1091-100. PubMed ID: 16648864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas.
    Esheba GE
    J Egypt Natl Canc Inst; 2013 Jun; 25(2):87-93. PubMed ID: 23719407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma.
    Alfsen GC; Reed W; Sandstad B; Kristensen GB; Abeler VM
    Cancer; 2003 Nov; 98(9):1880-9. PubMed ID: 14584070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
    Liao CL; Lee MY; Tyan YS; Kok LF; Wu TS; Koo CL; Wang PH; Chao KC; Han CP
    J Transl Med; 2009 May; 7():37. PubMed ID: 19476621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Yao CC; Kok LF; Lee MY; Wang PH; Wu TS; Tyan YS; Cheng YW; Kung MF; Han CP
    Arch Gynecol Obstet; 2009 Sep; 280(3):405-13. PubMed ID: 19153755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
    An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
    Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of high-risk human papillomavirus DNA and immunohistochemical expressions of p16, vimentin, ER, and PR in primary endocervical and endometrial adenocarcinomas.
    Xiong Y; Xiong YY; Xu ZG
    Eur J Gynaecol Oncol; 2016 Aug; 37(4):517-521. PubMed ID: 29894077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p16 INK4 and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16 INK4) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Tyan YS; Kok LF; Yao CC; Wang PH; Hsu JD; Tseng SW
    Virchows Arch; 2009 Oct; 455(4):353-61. PubMed ID: 19763614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Kok LF; Ruan A; Wu TS; Cheng YW; Tyan YS; Lin CY
    Int J Gynecol Pathol; 2009 Sep; 28(5):489-96. PubMed ID: 19696622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
    Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
    Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunofluorescence expression of Ki-67, p53 and cyclin inhibitors (p16ink4a, p21 and p27) in low-grade cervical lesions versus high-grade cervical lesions. Research study on cell cultures.
    Stănculescu R; Ceauşu M; Ceauşu Z; Bausic V
    Rom J Morphol Embryol; 2013; 54(3 Suppl):725-34. PubMed ID: 24322019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Koo CL; Kok LF; Lee MY; Wu TS; Cheng YW; Hsu JD; Ruan A; Chao KC; Han CP
    J Transl Med; 2009 Apr; 7():25. PubMed ID: 19366452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.